Pfizer Just Found a Way to Bring Color Back

Beyond that, doctors prescribe topical steroids, calcineurin inhibitors, and phototherapy off-label. In a US survey, only about 56% of dermatologists reported being satisfied with available treatments. A quarter of patients said they were flat-out frustrated.

An oral pill that works systemically could reach what topicals can't. It's the difference between mopping one tile at a time and turning on the sprinkler system.

The Science: Shutting Down the Attack Dog

Ritlecitinib works by blocking JAK3 and TEC family kinases, two groups of enzymes that act like amplifiers for the immune cells destroying melanocytes. It binds irreversibly to JAK3 at a spot (Cys-909) that's unique to that enzyme, which is why it doesn't mess with JAK1 or JAK2 the way broader inhibitors do.

The practical effect is two-fold. In active lesions (where melanocytes are actively being killed), ritlecitinib halts the destruction. In stable lesions (where the damage is done but no longer spreading), it lets surviving melanocytes or stem cells repopulate the skin and restore pigment. Phase 2 data showed this molecular story playing out in real patients: melanocyte markers increased in treated skin while inflammatory markers dropped.

Phase 2 also gave a preview of the dose-response curve. The effect was stronger at higher doses. Those numbers helped Pfizer pick the 50 mg and 100 mg doses for Phase 3.

Pfizer Needs This Win

Let's zoom out. Pfizer is staring down a patent cliff between 2026 and 2028, with several major products losing exclusivity. The company has been aggressively pruning its pipeline. That's not panic; it's triage. Pfizer is focusing its resources on programs with the clearest path to market.

Litfulo already has infrastructure. It's been approved for severe alopecia areata since June 2023 in the US, with subsequent approvals in the EU, Japan, and Canada. Doctors already know the drug. The manufacturing is set up. The safety database exists. Adding a vitiligo indication is like building a second restaurant in a kitchen you've already outfitted.

Pfizer said it intends to submit regulatory filings globally based on these results, though it hasn't committed to a specific timeline. Reading between the lines: with two positive pivotal trials, an already-approved molecule, and a well-characterized safety profile, a filing within the next 6 to 18 months seems plausible. First approvals could follow roughly a year after that.

The Competitive Landscape Ahead

Pfizer won't have the vitiligo market to itself forever. The global vitiligo therapeutics market is projected to reach the low single-digit billions by the mid-2020s. Several other JAK inhibitors and novel agents are in development across the industry.

But being first-to-market with an oral option carries enormous advantages. Ruxolitinib cream carved out a niche for mild, localized disease. Ritlecitinib could own the broader, more severe population that topicals can't adequately treat. That's a complementary market, not a competitive one (for now).

There's also the JAK inhibitor class label to navigate. All JAK inhibitors carry a boxed warning about serious infections, malignancy, cardiovascular events, and blood clots, based largely on data from older, sicker rheumatoid arthritis patients on a different JAK inhibitor. Whether that warning dampens uptake in a younger, healthier vitiligo population remains to be seen. The fact that adverse event rates in Phase 3 looked similar to placebo is reassuring, but it's a conversation every prescriber will have with every patient.

The Bottom Line

Vitiligo has been undertreated for decades. About 40% of US adults with the condition may not even have a diagnosis, let alone a prescription. Pfizer's Phase 3 data suggest that ritlecitinib can do something no oral drug has done before: meaningfully restore pigment in people whose immune systems have been erasing it.

The full dataset, with exact response rates and subgroup analyses, is still coming. But the direction is clear. For Pfizer, it's a pipeline win at exactly the moment the company needs one. For the millions of people living with vitiligo, it might be something bigger: validation that their condition deserves real medicine, not just concealer.

The First Toddlers Eligible for CRISPR Are Two Years Old

The FDA just approved a CRISPR gene therapy for kids as young as two, making Casgevy the first gene-editing treatment cleared for toddlers with sickle cell disease or beta thalassemia. The approval took just 53 days, and the implications stretch far beyond the 5,500 newly eligible children.